Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study

被引:25
|
作者
Rhee, Harin [1 ,2 ]
Berenger, Brendan [1 ]
Mehta, Ravindra L. [1 ]
Macedo, Etienne [1 ]
机构
[1] Univ Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA
[2] Pusan Natl Univ, Sch Med, Dept Internal Med, Pusan, South Korea
基金
美国国家卫生研究院;
关键词
CONTINUOUS RENAL REPLACEMENT; SYSTEMIC HEPARIN ANTICOAGULATION; CRITICALLY-ILL PATIENTS; CARE;
D O I
10.1053/j.ajkd.2021.01.017
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Regional citrate anticoagulation (RCA) is the preferred anticoagulation method for continuous kidney replacement therapy (CKRT) recommended by KDIGO. Limited availability of calcium-free solutions often imposes challenges to the implementation of RCA for CKRT (RCA-CKRT). The principal purpose of this study was to characterize the outcomes of RCA-CKRT using calcium-containing solutions. Study Design: Retrospective cohort study. Setting & Participants: We evaluated the safety and efficacy of RCA-CKRT with calcium-containing dialysate and replacement fluid used for 128 patients. A total of 571 filters and 1,227 days of CKRT were analyzed. Exposures: Liver disease, sepsis in the absence of liver disease, and sepsis with liver disease. Outcomes: Filter life and metabolic complications per 100 CKRT days. Analytical Approach: Linear mixed-effects model and generalized linear mixed-effects models. Results: The majority of patients were male (91; 71.1%), 32 (25%) had liver disease, and 29 (22.7%) had sepsis without liver disease. Median filter life was 50.0 (interquartile range, 22.0-118.0) hours, with a maximum of 322 hours, and was significantly lower (33.5 [interquartile range, 17.5-60.5] h) in patients with liver disease. Calcium-containing replacement solutions were used in 41.6% of all CKRT hours and reduced intravenous calcium requirements by 31.7%. Hypocalcemia (ionized calcium <0.85 mmol/L) and hypercalcemia (total calcium >10.6 mg/dL) were observed in 6.0 and 6.7 per 100 CKRT days, respectively. Citrate accumulation was observed in 13.3% of all patients and was associated with metabolic acidosis in 3.9%, which was not significantly different in patients with liver disease (9.3%; P = 0.2). Limitations: Lack of control groups that used calcium-free dialysate and replacement solutions with RCA-CKRT. Possible overestimation of filter life from incomplete data on cause of filter failure. Conclusions: Our study suggests that RCA-CKRT with calcium-containing solutions is feasible and safe in critically ill patients, including those with sepsis and liver disease.
引用
收藏
页码:550 / U70
页数:11
相关论文
共 50 条
  • [21] Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy: a narrative review
    Boer, Willem
    Verbrugghe, Walter
    Hoste, Eric
    Jacobs, Rita
    Jorens, Philippe G.
    ANNALS OF INTENSIVE CARE, 2023, 13 (01)
  • [22] Clinical efficacy of regional citrate anticoagulation in continuous renal replacement therapy: systematic review and meta-analysis
    Chang, Hong
    Gong, Yueying
    Li, Caixia
    Ma, Zengwen
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (08) : 8939 - 8951
  • [23] Continuous renal replacement therapy with regional citrate anticoagulation: do we really know the details?
    Lanckohr, Christian
    Hahnenkamp, Klaus
    Boschin, Matthias
    CURRENT OPINION IN ANESTHESIOLOGY, 2013, 26 (04) : 428 - 437
  • [24] Protocolized Regional Citrate Anticoagulation during Continuous Renal Replacement Therapy: A Single Center Experience
    Pachisia, Anant, V
    Kumar, Praveen G.
    Harne, Rahul
    Jagadeesh, K. N.
    Patel, Sweta J.
    Pal, Divya
    Tyagi, Pooja
    Pattajoshi, Swagat
    Brar, Keerti
    Patel, Parimal B.
    Zatakiya, Ronak
    Chandra, Subhash
    Govil, Deepak
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2024, 28 (09) : 859 - 865
  • [25] Continuous veno-venous hemofiltration using a phosphate-containing replacement fluid in the setting of regional citrate anticoagulation
    Morabito, Santo
    Pistolesi, Valentina
    Tritapepe, Luigi
    Vitaliano, Elio
    Zeppilli, Laura
    Polistena, Francesca
    Fiaccadori, Enrico
    Pierucci, Alessandro
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2013, 36 (12) : 845 - 852
  • [26] Risks and benefits of citrate anticoagulation for continuous renal replacement therapy
    Shum, H. P.
    Yan, W. W.
    Chan, T. M.
    HONG KONG MEDICAL JOURNAL, 2015, 21 (02) : 149 - 154
  • [27] Advances in Continuous Renal Replacement Therapy: Citrate Anticoagulation Update
    Tolwani, Ashita
    Wille, Keith M.
    BLOOD PURIFICATION, 2012, 34 (02) : 88 - 93
  • [28] Citrate Anticoagulation During Continuous Renal Replacement Therapy in Pediatric Critical Care
    Davis, T. Keefe
    Neumayr, Tara
    Geile, Kira
    Doctor, Allan
    Hmeil, Paul
    PEDIATRIC CRITICAL CARE MEDICINE, 2014, 15 (05) : 471 - 485
  • [29] Regional Citrate Anticoagulation versus No-Anticoagulation for Continuous Venovenous Hemofiltration in Acute Severe Hypernatremia Patients with Increased Bleeding Risk: A Retrospective Cohort Study
    Zhao, Lijuan
    Ma, Feng
    Yu, Yan
    Li, Yangping
    Wang, Yan
    He, Lijie
    Zhou, Meilan
    Tian, Xiujuan
    Jing, Rui
    Li, Li
    Li, Lu
    Huang, Chen
    Bai, Ming
    Sun, Shiren
    BLOOD PURIFICATION, 2020, 49 (1-2) : 44 - 54
  • [30] Comparison of diluted vs concentrated regional citrate anticoagulation in continuous renal replacement therapy: A quasi-experimental study
    Mateos-Davila, Almudena
    Roig, Antonio Jorge Betbese
    Rodriguez, Jose Alberto Santos
    Guix-Comellas, Eva Maria
    NURSING IN CRITICAL CARE, 2024, 29 (05) : 1005 - 1014